I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| epithelial cell | 3 studies | 23% ± 5% | |
| GABAergic neuron | 3 studies | 31% ± 1% | |
| glutamatergic neuron | 3 studies | 39% ± 4% | |
| oligodendrocyte precursor cell | 3 studies | 21% ± 5% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| epithelial cell | 3 studies | 23% ± 5% | |
| GABAergic neuron | 3 studies | 31% ± 1% | |
| glutamatergic neuron | 3 studies | 39% ± 4% | |
| oligodendrocyte precursor cell | 3 studies | 21% ± 5% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| brain | 4 studies | 28% ± 8% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| esophagus | 100% | 616.36 | 1445 / 1445 | 100% | 11.24 | 183 / 183 |
| ovary | 100% | 699.45 | 180 / 180 | 100% | 10.39 | 430 / 430 |
| uterus | 100% | 695.36 | 170 / 170 | 100% | 15.03 | 459 / 459 |
| breast | 100% | 729.17 | 459 / 459 | 100% | 14.54 | 1116 / 1118 |
| prostate | 100% | 684.50 | 245 / 245 | 100% | 11.70 | 500 / 502 |
| skin | 100% | 903.37 | 1809 / 1809 | 100% | 14.94 | 470 / 472 |
| bladder | 100% | 575.52 | 21 / 21 | 99% | 10.73 | 501 / 504 |
| thymus | 100% | 683.09 | 653 / 653 | 99% | 7.47 | 601 / 605 |
| brain | 99% | 459.61 | 2627 / 2642 | 100% | 8.65 | 704 / 705 |
| liver | 100% | 433.85 | 226 / 226 | 99% | 7.32 | 402 / 406 |
| lung | 99% | 560.89 | 570 / 578 | 100% | 10.24 | 1155 / 1155 |
| pancreas | 99% | 429.99 | 325 / 328 | 99% | 6.90 | 176 / 178 |
| stomach | 100% | 482.54 | 359 / 359 | 98% | 9.94 | 280 / 286 |
| intestine | 100% | 656.84 | 966 / 966 | 98% | 9.35 | 514 / 527 |
| kidney | 100% | 514.74 | 89 / 89 | 97% | 7.23 | 877 / 901 |
| adrenal gland | 100% | 718.64 | 258 / 258 | 81% | 3.95 | 187 / 230 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 10.27 | 29 / 29 |
| spleen | 100% | 1050.29 | 241 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 14.34 | 45 / 45 |
| ureter | 0% | 0 | 0 / 0 | 100% | 4.30 | 1 / 1 |
| adipose | 100% | 667.99 | 1203 / 1204 | 0% | 0 | 0 / 0 |
| blood vessel | 99% | 384.70 | 1324 / 1335 | 0% | 0 | 0 / 0 |
| heart | 97% | 287.80 | 837 / 861 | 0% | 0 | 0 / 0 |
| muscle | 97% | 294.50 | 776 / 803 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 96% | 7.67 | 77 / 80 |
| peripheral blood | 95% | 616.31 | 887 / 929 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0006490 | Biological process | oligosaccharide-lipid intermediate biosynthetic process |
| GO_0006487 | Biological process | protein N-linked glycosylation |
| GO_0006488 | Biological process | dolichol-linked oligosaccharide biosynthetic process |
| GO_0098553 | Cellular component | lumenal side of endoplasmic reticulum membrane |
| GO_0016020 | Cellular component | membrane |
| GO_0005789 | Cellular component | endoplasmic reticulum membrane |
| GO_0046527 | Molecular function | glucosyltransferase activity |
| GO_0004583 | Molecular function | dolichyl-phosphate-glucose-glycolipid alpha-glucosyltransferase activity |
| GO_0042281 | Molecular function | dolichyl pyrophosphate Man9GlcNAc2 alpha-1,3-glucosyltransferase activity |
| Gene name | ALG6 |
| Protein name | Alpha-1,3-glucosyltransferase (EC 2.4.1.-) Dolichyl pyrophosphate Man9GlcNAc2 alpha-1,3-glucosyltransferase (EC 2.4.1.267) (Asparagine-linked glycosylation protein 6 homolog) (Dol-P-Glc:Man(9)GlcNAc(2)-PP-Dol alpha-1,3-glucosyltransferase) (Dolichyl-P-Glc:Man9GlcNAc2-PP-dolichyl glucosyltransferase) ALG6 alpha-1,3-glucosyltransferase |
| Synonyms | My046 |
| Description | FUNCTION: Adds the first glucose residue to the lipid-linked oligosaccharide precursor for N-linked glycosylation. Transfers glucose from dolichyl phosphate glucose (Dol-P-Glc) onto the lipid-linked oligosaccharide Man(9)GlcNAc(2)-PP-Dol. FUNCTION: Adds the first glucose residue to the lipid-linked oligosaccharide precursor for N-linked glycosylation. Transfers glucose from dolichyl phosphate glucose (Dol-P-Glc) onto the lipid-linked oligosaccharide Man(9)GlcNAc(2)-PP-Dol. . FUNCTION: Adds the first glucose residue to the lipid-linked oligosaccharide precursor for N-linked glycosylation. Transfers glucose from dolichyl phosphate glucose (Dol-P-Glc) onto the lipid-linked oligosaccharide Man(9)GlcNAc(2)-PP-Dol. . FUNCTION: Adds the first glucose residue to the lipid-linked oligosaccharide precursor for N-linked glycosylation. Transfers glucose from dolichyl phosphate glucose (Dol-P-Glc) onto the lipid-linked oligosaccharide Man(9)GlcNAc(2)-PP-Dol. . FUNCTION: Adds the first glucose residue to the lipid-linked oligosaccharide precursor for N-linked glycosylation. Transfers glucose from dolichyl phosphate glucose (Dol-P-Glc) onto the lipid-linked oligosaccharide Man(9)GlcNAc(2)-PP-Dol. . |
| Accessions | ENST00000649570.1 Q9Y672 A0A3B3IS62 S4R350 ENST00000647818.1 ENST00000603108.6 ENST00000650494.1 R4GMS5 A0A3B3ITL6 A0A3B3ITI5 ENST00000648964.1 ENST00000263440.6 ENST00000487136.2 A0A3B3ITD6 |
